114 related articles for article (PubMed ID: 38064349)
1. ASCL1 and ASCL2 Define Distinct States of Neuroendocrine Prostate Cancer.
Cancer Discov; 2023 Dec; ():OF1. PubMed ID: 38064349
[TBL] [Abstract][Full Text] [Related]
2. Systematic analysis of the achaete-scute complex-like gene signature in clinical cancer patients.
Wang CY; Shahi P; Huang JT; Phan NN; Sun Z; Lin YC; Lai MD; Werb Z
Mol Clin Oncol; 2017 Jan; 6(1):7-18. PubMed ID: 28123722
[TBL] [Abstract][Full Text] [Related]
3. Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer.
Wang Z; Wang T; Hong D; Dong B; Wang Y; Huang H; Zhang W; Lian B; Ji B; Shi H; Qu M; Gao X; Li D; Collins C; Wei G; Xu C; Lee HJ; Huang J; Li J
iScience; 2022 Jul; 25(7):104576. PubMed ID: 35789834
[TBL] [Abstract][Full Text] [Related]
4. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
Augustyn A; Borromeo M; Wang T; Fujimoto J; Shao C; Dospoy PD; Lee V; Tan C; Sullivan JP; Larsen JE; Girard L; Behrens C; Wistuba II; Xie Y; Cobb MH; Gazdar AF; Johnson JE; Minna JD
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14788-93. PubMed ID: 25267614
[TBL] [Abstract][Full Text] [Related]
5. Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.
Kudoh S; Tenjin Y; Kameyama H; Ichimura T; Yamada T; Matsuo A; Kudo N; Sato Y; Ito T
Histochem Cell Biol; 2020 Jun; 153(6):443-456. PubMed ID: 32170367
[TBL] [Abstract][Full Text] [Related]
6. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE
Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466
[TBL] [Abstract][Full Text] [Related]
7. ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer.
Nouruzi S; Ganguli D; Tabrizian N; Kobelev M; Sivak O; Namekawa T; Thaper D; Baca SC; Freedman ML; Aguda A; Davies A; Zoubeidi A
Nat Commun; 2022 Apr; 13(1):2282. PubMed ID: 35477723
[TBL] [Abstract][Full Text] [Related]
8. The Epithelial Sodium Channel (αENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors.
He M; Liu S; Gallolu Kankanamalage S; Borromeo MD; Girard L; Gazdar AF; Minna JD; Johnson JE; Cobb MH
Transl Oncol; 2018 Apr; 11(2):292-299. PubMed ID: 29413762
[TBL] [Abstract][Full Text] [Related]
9. ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.
Miyakawa K; Miyashita N; Horie M; Terasaki Y; Tanaka H; Urushiyama H; Fukuda K; Okabe Y; Ishii T; Kuwahara N; Suzuki HI; Nagase T; Saito A
Cancer Sci; 2022 Nov; 113(11):3932-3946. PubMed ID: 35789143
[TBL] [Abstract][Full Text] [Related]
10. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
[TBL] [Abstract][Full Text] [Related]
11. An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1-Positive Lung Adenocarcinomas.
Miyashita N; Horie M; Suzuki HI; Yoshihara M; Djureinovic D; Persson J; Brunnström H; Lindskog C; Elfving H; Micke P; Saito A; Nagase T
J Thorac Oncol; 2018 Nov; 13(11):1676-1691. PubMed ID: 30121393
[TBL] [Abstract][Full Text] [Related]
12. ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation.
Kosari F; Ida CM; Aubry MC; Yang L; Kovtun IV; Klein JL; Li Y; Erdogan S; Tomaszek SC; Murphy SJ; Bolette LC; Kolbert CP; Yang P; Wigle DA; Vasmatzis G
Oncogene; 2014 Jul; 33(29):3776-83. PubMed ID: 24037524
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.
von Hardenberg J; Hartmann S; Nitschke K; Worst TS; Ting S; Reis H; Nuhn P; Weis CA; Erben P
Clin Genitourin Cancer; 2019 Apr; 17(2):145-153.e5. PubMed ID: 30709785
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary Neuroendocrine Cells and Small Cell Lung Carcinoma: Immunohistochemical Study Focusing on Mechanisms of Neuroendocrine Differentiation.
Ito T; Kudoh S; Fujino K; Sanada M; Tenjin Y; Saito H; Nakaishi-Fukuchi Y; Kameyama H; Ichimura T; Udaka N; Kudo N; Matsuo A; Sato Y
Acta Histochem Cytochem; 2022 Jun; 55(3):75-83. PubMed ID: 35821751
[TBL] [Abstract][Full Text] [Related]
15. EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.
Bhinge K; Yang L; Terra S; Nasir A; Muppa P; Aubry MC; Yi J; Janaki N; Kovtun IV; Murphy SJ; Halling G; Rahi H; Mansfield A; de Andrade M; Yang P; Vasmatzis G; Peikert T; Kosari F
Oncotarget; 2017 Apr; 8(16):27155-27165. PubMed ID: 28460442
[TBL] [Abstract][Full Text] [Related]
16. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.
Labrecque MP; Brown LG; Coleman IM; Lakely B; Brady NJ; Lee JK; Nguyen HM; Li D; Hanratty B; Haffner MC; Rickman DS; True LD; Lin DW; Lam HM; Alumkal JJ; Corey E; Nelson PS; Morrissey C
Cancer Res; 2021 Sep; 81(18):4736-4750. PubMed ID: 34312180
[TBL] [Abstract][Full Text] [Related]
17. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
[TBL] [Abstract][Full Text] [Related]
18. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.
Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B
J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical study of the neural development transcription factors (TTF1, ASCL1 and BRN2) in neuroendocrine prostate tumours.
Rodríguez-Zarco E; Vallejo-Benítez A; Umbría-Jiménez S; Pereira-Gallardo S; Pabón-Carrasco S; Azueta A; González-Cámpora R; Espinal PS; García-Escudero A
Actas Urol Esp; 2017 Oct; 41(8):529-534. PubMed ID: 28285791
[TBL] [Abstract][Full Text] [Related]
20. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
